DAPA-HF blazing a trail for sodium-glucose co-transporter-2 inhibitors in heart failure

shutterstock_515472277
Phase III trial looked at the outcomes of AstraZeneca’s Farxiga use in patients with heart failure with reduced ejection fraction, in patients both with and without diabetes.